Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4527-4534.DOI: 10.12114/j.issn.1007-9572.2022.0833
Special Issue: 肿瘤最新文章合集; 肺癌最新文章合集
• Article • Previous Articles Next Articles
Received:
2022-10-15
Revised:
2023-02-25
Published:
2023-12-20
Online:
2023-05-26
Contact:
CUI Huijuan
通讯作者:
崔慧娟
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0833
临床特征 | 例数 | 百分比(%) | 临床特征 | 例数 | 百分比(%) |
---|---|---|---|---|---|
性别 | 吸烟史 | ||||
男 | 95 | 43.8 | 无 | 164 | 75.6 |
女 | 122 | 56.2 | 轻度 | 8 | 3.7 |
肿瘤部位 | 中度 | 13 | 6.0 | ||
双肺 | 6 | 2.8 | 重度 | 32 | 14.7 |
左肺 | 115 | 39.2 | 饮酒史 | ||
右肺 | 96 | 58.0 | 有 | 31 | 14.3 |
肿瘤分期 | 无 | 186 | 85.7 | ||
Ⅰ期 | 31 | 14.3 | 家族史 | ||
Ⅱ期 | 17 | 7.8 | 有 | 37 | 17.1 |
Ⅲ期 | 24 | 11.1 | 无 | 180 | 82.9 |
Ⅳ期 | 145 | 66.8 | 肿瘤史 | ||
是否手术 | 有 | 23 | 10.6 | ||
是 | 123 | 56.7 | 无 | 194 | 89.4 |
否 | 94 | 43.3 | 肺病史 | ||
胸膜转移 | 有 | 24 | 11.1 | ||
是 | 86 | 39.6 | 无 | 193 | 88.9 |
否 | 131 | 60.4 |
Table 1 Baseline characteristics of 217 NSCLC patients receiving two genetic tests before and after progression
临床特征 | 例数 | 百分比(%) | 临床特征 | 例数 | 百分比(%) |
---|---|---|---|---|---|
性别 | 吸烟史 | ||||
男 | 95 | 43.8 | 无 | 164 | 75.6 |
女 | 122 | 56.2 | 轻度 | 8 | 3.7 |
肿瘤部位 | 中度 | 13 | 6.0 | ||
双肺 | 6 | 2.8 | 重度 | 32 | 14.7 |
左肺 | 115 | 39.2 | 饮酒史 | ||
右肺 | 96 | 58.0 | 有 | 31 | 14.3 |
肿瘤分期 | 无 | 186 | 85.7 | ||
Ⅰ期 | 31 | 14.3 | 家族史 | ||
Ⅱ期 | 17 | 7.8 | 有 | 37 | 17.1 |
Ⅲ期 | 24 | 11.1 | 无 | 180 | 82.9 |
Ⅳ期 | 145 | 66.8 | 肿瘤史 | ||
是否手术 | 有 | 23 | 10.6 | ||
是 | 123 | 56.7 | 无 | 194 | 89.4 |
否 | 94 | 43.3 | 肺病史 | ||
胸膜转移 | 有 | 24 | 11.1 | ||
是 | 86 | 39.6 | 无 | 193 | 88.9 |
否 | 131 | 60.4 |
进展前 | 进展后 | 合计 | |
---|---|---|---|
阴性 | 阳性 | ||
阴性 | 60(27.6) | 10(4.6) | 70(32.3) |
阳性 | 35(16.1) | 112(51.6) | 147(67.7) |
合计 | 95(43.8) | 122(56.2) | 217(100.0) |
Table 2 Comparison of EGFR gene mutations before and after treatment in 217 patients with NSCLC
进展前 | 进展后 | 合计 | |
---|---|---|---|
阴性 | 阳性 | ||
阴性 | 60(27.6) | 10(4.6) | 70(32.3) |
阳性 | 35(16.1) | 112(51.6) | 147(67.7) |
合计 | 95(43.8) | 122(56.2) | 217(100.0) |
突变状态 | PD前 | PD后 | χ2值 | P值 |
---|---|---|---|---|
野生型 | 70(32.3) | 95(43.8) | 6.11 | 0.013 |
突变型 | 147(67.7) | 122(56.2) | 6.11 | 0.013 |
19 DEL | 64(29.5) | 43(19.8) | 5.47 | 0.019 |
21 L858R | 74(34.1) | 52(24.0) | 5.41 | 0.020 |
20 T790M | 2(0.9) | 45(20.7) | 42.10 | <0.001 |
少见突变 | 20(9.2) | 84(38.7) | 51.80 | <0.001 |
Table 3 Distribution of EGFR gene mutations from 217 NSCLC patients before and after treatment
突变状态 | PD前 | PD后 | χ2值 | P值 |
---|---|---|---|---|
野生型 | 70(32.3) | 95(43.8) | 6.11 | 0.013 |
突变型 | 147(67.7) | 122(56.2) | 6.11 | 0.013 |
19 DEL | 64(29.5) | 43(19.8) | 5.47 | 0.019 |
21 L858R | 74(34.1) | 52(24.0) | 5.41 | 0.020 |
20 T790M | 2(0.9) | 45(20.7) | 42.10 | <0.001 |
少见突变 | 20(9.2) | 84(38.7) | 51.80 | <0.001 |
临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 | 临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|---|
性别 | 2.49 | 0.114 | 家族史 | 0.90 | 0.344 | ||||||
男 | 95 | 24(35.8) | 71(47.3) | 有 | 37 | 9(13.4) | 28(18.7) | ||||
女 | 122 | 43(64.2) | 79(52.7) | 无 | 180 | 58(86.6) | 122(81.3) | ||||
年龄 | 1.09 | 0.297 | 肿瘤史 | 0 | 0.961 | ||||||
<60岁 | 69 | 18(26.9) | 51(34.0) | 有 | 23 | 7(10.4) | 16(10.7) | ||||
≥60岁 | 148 | 49(73.1) | 99(66.0) | 无 | 194 | 60(89.6) | 134(89.3) | ||||
肿瘤部位 | 0.20 | 0.905 | 肺病史 | 4.62 | 0.032 | ||||||
双肺 | 6 | 2(3.0) | 4(2.7) | 有 | 24 | 12(17.9) | 12(8.0) | ||||
左肺 | 115 | 34(50.7) | 81(54.0) | 无 | 193 | 55(82.1) | 138(92.0) | ||||
右肺 | 96 | 31(46.3) | 65(43.3) | 化学治疗 | 0.22 | 0.636 | |||||
肿瘤分期 | 1.00 | 0.318 | 有 | 76 | 25(37.3) | 51(34.0) | |||||
早期(Ⅰ~Ⅱ期) | 48 | 12(17.9) | 36(24.0) | 无 | 141 | 42(62.7) | 99(66.0) | ||||
中晚期(Ⅲ~Ⅳ期) | 169 | 55(82.1) | 114(76.0) | 放射治疗 | 0.04 | 0.848 | |||||
是否手术 | 0.34 | 0.588 | 有 | 26 | 7(10.4) | 17(11.3) | |||||
是 | 123 | 36(53.7) | 87(58.0) | 无 | 191 | 60(89.6) | 133(88.7) | ||||
否 | 94 | 31(46.3) | 63(42.0) | 免疫治疗 | 0 | 0.981 | |||||
胸膜转移 | 3.75 | 0.053 | 有 | 8 | 3(4.5) | 5(3.3) | |||||
是 | 86 | 33(49.2) | 53(35.3) | 无 | 209 | 64(95.5) | 145(96.7) | ||||
否 | 131 | 34(50.8) | 97(64.7) | 靶向治疗 | 11.51 | 0.001 | |||||
吸烟史 | 0.65 | 0.419 | 有 | 139 | 54(80.6) | 85(56.7) | |||||
有 | 172 | 53(79.1) | 111(74.0) | 无 | 78 | 13(19.4) | 65(43.3) | ||||
无 | 45 | 14(20.9) | 39(26.0) | 中医治疗 | 0.03 | 0.860 | |||||
饮酒史 | 0.44 | 0.509 | 有 | 92 | 29(43.3) | 63(42.0) | |||||
有 | 31 | 8(11.9) | 23(15.3) | 无 | 125 | 38(56.7) | 87(58.0) | ||||
无 | 186 | 59(88.1) | 127(84.7) |
Table 4 Clinical characteristics of 217 patients with NSCLC grouped by the prevalence of geneclearance
临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 | 临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|---|
性别 | 2.49 | 0.114 | 家族史 | 0.90 | 0.344 | ||||||
男 | 95 | 24(35.8) | 71(47.3) | 有 | 37 | 9(13.4) | 28(18.7) | ||||
女 | 122 | 43(64.2) | 79(52.7) | 无 | 180 | 58(86.6) | 122(81.3) | ||||
年龄 | 1.09 | 0.297 | 肿瘤史 | 0 | 0.961 | ||||||
<60岁 | 69 | 18(26.9) | 51(34.0) | 有 | 23 | 7(10.4) | 16(10.7) | ||||
≥60岁 | 148 | 49(73.1) | 99(66.0) | 无 | 194 | 60(89.6) | 134(89.3) | ||||
肿瘤部位 | 0.20 | 0.905 | 肺病史 | 4.62 | 0.032 | ||||||
双肺 | 6 | 2(3.0) | 4(2.7) | 有 | 24 | 12(17.9) | 12(8.0) | ||||
左肺 | 115 | 34(50.7) | 81(54.0) | 无 | 193 | 55(82.1) | 138(92.0) | ||||
右肺 | 96 | 31(46.3) | 65(43.3) | 化学治疗 | 0.22 | 0.636 | |||||
肿瘤分期 | 1.00 | 0.318 | 有 | 76 | 25(37.3) | 51(34.0) | |||||
早期(Ⅰ~Ⅱ期) | 48 | 12(17.9) | 36(24.0) | 无 | 141 | 42(62.7) | 99(66.0) | ||||
中晚期(Ⅲ~Ⅳ期) | 169 | 55(82.1) | 114(76.0) | 放射治疗 | 0.04 | 0.848 | |||||
是否手术 | 0.34 | 0.588 | 有 | 26 | 7(10.4) | 17(11.3) | |||||
是 | 123 | 36(53.7) | 87(58.0) | 无 | 191 | 60(89.6) | 133(88.7) | ||||
否 | 94 | 31(46.3) | 63(42.0) | 免疫治疗 | 0 | 0.981 | |||||
胸膜转移 | 3.75 | 0.053 | 有 | 8 | 3(4.5) | 5(3.3) | |||||
是 | 86 | 33(49.2) | 53(35.3) | 无 | 209 | 64(95.5) | 145(96.7) | ||||
否 | 131 | 34(50.8) | 97(64.7) | 靶向治疗 | 11.51 | 0.001 | |||||
吸烟史 | 0.65 | 0.419 | 有 | 139 | 54(80.6) | 85(56.7) | |||||
有 | 172 | 53(79.1) | 111(74.0) | 无 | 78 | 13(19.4) | 65(43.3) | ||||
无 | 45 | 14(20.9) | 39(26.0) | 中医治疗 | 0.03 | 0.860 | |||||
饮酒史 | 0.44 | 0.509 | 有 | 92 | 29(43.3) | 63(42.0) | |||||
有 | 31 | 8(11.9) | 23(15.3) | 无 | 125 | 38(56.7) | 87(58.0) | ||||
无 | 186 | 59(88.1) | 127(84.7) |
[1] |
|
[2] |
|
[3] |
|
[4] |
吴兆明,刘平,余玲玲,等. 结直肠癌患者循环肿瘤DNA定量KRAS基因突变的检测[J]. 基础医学与临床,2018,38(2):180-184. DOI:10.16352/j.issn.1001-6325.2018.02.007.
|
[5] |
|
[6] |
付光明,刘平,吴芳,等. 一代EGFR-TKIs治疗后进展的晚期NSCLC外周血T790M突变特征[J]. 中华肺部疾病杂志(电子版),2021,14(2):169-173.
|
[7] |
金鹏,冯虎,刘倩倩,等. 早期非小细胞肺癌高复发风险相关基因的生物信息学分析[J]. 中国生物制品学杂志,2018,31(1):35-40. DOI:10.13200/j.cnki.cjb.002050.
|
[8] |
刘平,吴羽华,周立娟,等. 不同基因分型晚期非小细胞肺癌患者的预后分析[J]. 中国肺癌杂志,2017,20(11):741-750. DOI:10.3779/j.issn.1009-3419.2017.11.04.
|
[9] |
中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志,2021,43(6):591-621. DOI:10.3760/cma.j.cn112152-20210207-00118.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
中华医学会病理学分会,国家病理质控中心,中华医学会肿瘤学分会肺癌学组,等. 非小细胞肺癌分子病理检测临床实践指南(2021版)[J]. 中华病理学杂志,2021,50(4):323-332. DOI:10.3760/cma.j.cn112151-20201220-00945.
|
[17] |
范夷平,杜名,于夫尧,等. 肺癌驱动基因、检测方法及靶向治疗研究进展[J]. 现代肿瘤医学,2020,28(2):330-334.
|
[18] |
|
[19] |
|
[20] |
|
[1] | CUI Xiaona, FENG Ruixia, HAN Yupeng, ZHOU Yaoyao, LIU Xiaojun, LI Jianchao. A Comparative Study on Clinical Effects of Combined Auxiliary Sequence of VA-ECMO and IABP on Acute Myocardial Infarction Complicated with Cardiogenic Shock [J]. Chinese General Practice, 2023, 26(35): 4439-4445. |
[2] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[3] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[4] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[5] | SHI Xiaoqi, LUO Nandu, HUANG Jiaojiao, DU Zuochen, HUANG Pei, CAO Xiuli, CHEN Yan, HE Zhixu. Correlation between Aspartate Aminotransferase/Alanine Aminotransferase and Prognosis of Hemophagocytic Lymphohistiocytosis in Children [J]. Chinese General Practice, 2023, 26(30): 3801-3808. |
[6] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[7] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[8] | TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348. |
[9] | SUN Shuaigang, SHENG Xiaoxiao, ZHANG Wenhui, TIAN Huijuan, ZHAI Yaling. The Analysis of Clinicopathological Characters and Short-term Prognosis in Idiopathic Membranous Nephropathy Patients with Immunoglobulin G4 Combined with Other Different Immunoglobulin G Subtypes Deposition [J]. Chinese General Practice, 2023, 26(21): 2632-2638. |
[10] | CHEN Bo, LIU Qing. Tricho-rhino-phalangeal Syndrome with Growth Hormone Deficiency: a Case Report and Literature Review [J]. Chinese General Practice, 2023, 26(21): 2686-2689. |
[11] | ZHAO Zewei, KANG Ning, GUO Fengli, WANG Zhongyu, ZHENG Xiangqian. Effect of Aurora Kinase A Expression on Biochemical Cure in Patients after Medullary Thyroid Cancer Resection [J]. Chinese General Practice, 2023, 26(20): 2508-2512. |
[12] | ZHANG Kang, JI Wenshuai, KONG Xinxin, DU Chen, XIE Kai, WANG Haifeng. Predictive Efficacies of SOFA Score, CURB-65 Score and PSI Score for 28-day Mortality in Patients with Severe Pneumonia: a Comparative Study [J]. Chinese General Practice, 2023, 26(18): 2217-2222. |
[13] | WANG Jun, WU Jiafei, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, LI Hui. Efficacy and Prognostic Effect of Daratumumab-based Chemotherapy Regimen in Multiple Myeloma: a Real-world Study [J]. Chinese General Practice, 2023, 26(18): 2256-2262. |
[14] | GUO Ting, ZHANG Jian, DING Ying, YANG Xiaoqing, ZHAI Wensheng, SONG Chundong, ZHANG Xia, ZHANG Bo, GAO Xuguang, LIU Liya. Autosomal Dominant Alport Syndrome Caused by a Novel COL4A4 Gene Mutation: a Case Report and Literature Review [J]. Chinese General Practice, 2023, 26(18): 2306-2310. |
[15] | MA Yong, GAO Weibo, ZHU Jihong. Risk Factors of Thrombocytopenia Caused by Pyogenic Liver Abscess [J]. Chinese General Practice, 2023, 26(17): 2120-2124. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||